Speakers: Dr. Steve Smith, Business Development Director at GemPharmatech

Alzheimer’s disease (AD) affects an estimated 24 million people worldwide. Although several medications have been FDA approved for the treatment of AD, there is still an urgent need for new therapies because like other forms of dementia, AD is complex and difficult to treat with one drug or intervention.

We know how important innovative, translatable animal models are to research that focuses on accelerating the identification of new drug targets and developing new therapies for diseases like AD. In this webinar we will introduce you to our novel AD mouse models, specifically our FAD4T mice and our Next-Generation AD models. We will also describe other exciting models available for researching various neurodegenerative diseases.

свернуть